{"id":"deferred-aflibercept","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain / discomfort"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a VEGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. This construct binds circulating VEGF and PlGF with high affinity, preventing their interaction with endothelial cell receptors and thereby inhibiting pathological angiogenesis and vascular permeability. The 'deferred' designation likely refers to a delayed-treatment or treatment-deferral study design rather than a mechanistic modification.","oneSentence":"Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:56.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Age-related macular degeneration (AMD)"}]},"trialDetails":[{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT04469595","phase":"PHASE4","title":"A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimera Sciences","startDate":"2020-08-31","conditions":"Diabetic Macular Edema","enrollment":300},{"nctId":"NCT03321513","phase":"PHASE3","title":"DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2017-12-07","conditions":"Diabetic Macular Edema","enrollment":270},{"nctId":"NCT02634333","phase":"PHASE3","title":"Anti-VEGF Treatment for Prevention of PDR/DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":399},{"nctId":"NCT05731089","phase":"NA","title":"IVI Aflibercept Before and After Phaco in DME.","status":"COMPLETED","sponsor":"Al Hadi Hospital","startDate":"2019-09-01","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02858076","phase":"PHASE2, PHASE3","title":"Anti-VEGF vs. Prompt Vitrectomy for VH From PDR","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-11","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":205},{"nctId":"NCT04707027","phase":"NA","title":"Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-11-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":80},{"nctId":"NCT01909791","phase":"PHASE3","title":"Treatment for CI-DME in Eyes With Very Good VA Study","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2013-10","conditions":"Diabetic Macular Edema","enrollment":702},{"nctId":"NCT03197480","phase":"PHASE4","title":"Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME","status":"UNKNOWN","sponsor":"Singapore National Eye Centre","startDate":"2019-04-17","conditions":"Diabetic Macular Edema","enrollment":36},{"nctId":"NCT02788877","phase":"PHASE4","title":"Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2016-04-10","conditions":"Macular Edema, Diabetic","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["intravitreal anti-vascular endothelial growth factor","Eylea","intravitreal anti-VEGF"],"phase":"phase_3","status":"active","brandName":"Deferred aflibercept","genericName":"Deferred aflibercept","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors. Used for Diabetic macular edema (DME), Retinal vein occlusion (RVO), Age-related macular degeneration (AMD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}